Arlene Sharpe, MD, PhD is the George Fabyan Professor of Comparative Pathology, Head of the Division of Immunology, and Interim Co-Chair of the Department of Microbiology and Immunobiology at Harvard Medical School. She is a member of the Department of Pathology at Brigham and Women’s Hospital, an Associate Member at the Broad Institute of MIT and Harvard, Leader of the Cancer Immunology Program at the Dana-Farber/Harvard Cancer Center, and Co-Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital.
Dr. Sharpe earned her MD and PhD degrees from Harvard Medical School and completed her residency in Pathology at Brigham and Women’s Hospital. Dr. Sharpe is a leader in the field of T cell costimulation. Her laboratory has discovered and elucidated the functions of T cell costimulatory pathways, including the immunoinhibitory functions of the CTLA-4 and PD-1 pathways, which have become exceptionally promising targets for cancer immunotherapy. Her laboratory currently focuses on the roles of T cell costimulatory pathways in regulating T cell tolerance and effective antimicrobial and antitumor immunity and translating fundamental understanding of T cell costimulation into new therapies for autoimmune diseases and cancer. Dr. Sharpe has published over 300 papers and was listed by Thomas Reuters as one of the most Highly Cited Researchers (top 1%) in 2014, 2015, and 2017 and as a Citation Laureate in 2016. She received the William B. Coley Award for Distinguished Research in Tumor immunology in 2014 and the Warren Alpert Foundation Prize in 2017 for her contributions to the discovery of PD-1 pathway.